BrainsWay Ltd.

OVERVALUEDBWAY · NASDAQ · Healthcare
BWAY·NASDAQ·Healthcare
OVERVALUED
BrainsWay Ltd.
42.3%downside
MARKET PRICE
$16.40
FAIR PRICE
$9.47
MARGIN
$6.93
UNDERVALUEDFAIROVERVALUED
P/E RATIO
52.5x
DIV. YIELD
N/A
ROE
9.5%
MARKET CAP
$623M
FPI
fairpriceindex.com

FAIR PRICE VALUATION

42.3%downside

Updated daily

Model: DCF 50% · Relative 30% · Consensus 20%

MARKET PRICE

$16.40

FAIR PRICE

$9.47

MARGIN

$6.93

UNDERVALUEDFAIROVERVALUED

P/E Ratio

52.5x

What is P/E? →

Div. Yield

N/A

ROE

9.5%

Average

Market Cap

$623M

Small-cap

NOW AVAILABLE

Get notified when BWAY's fair price changes

Push notifications when BWAY's valuation shifts. Available on iOS and Android.

Download on the App StoreGet it on Google Play

FPI RATING

4.1/ 10

Low debt levels, but limited growth momentum and volatile earnings pattern.

Analytical data, not an investment recommendation. Updated daily.

How we calculate this ↗

MARGIN OF SAFETY

A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.

$7.58CONSERVATIVE ENTRY
$9.47FAIR PRICE
$16.40MARKET PRICE

SAFETY MARGIN

20%

Below fair value

ENTRY LEVEL

$7.58

Fair price × 0.80

DISTANCE

53.8%

Price to entry level

At the current price of $16.40, BWAY trades 53.8% above the conservative entry level of $7.58. This entry level represents a 20% margin of safety below the calculated fair price of $9.47 — a buffer that accounts for estimation uncertainty in the valuation model.

Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗

VALUATION HISTORY

Loading chart data...

P/E RATIO HISTORY

Loading chart data...

METHODOLOGY

How we calculate BWAY's fair price

BrainsWay Ltd.'s fair price of $9.47 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $16.40, BWAY trades 42.3% above its calculated fair value.

DCF MODEL · 50%

Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting BWAY's risk profile.

RELATIVE · 30%

Comparing BWAY's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.

ANALYST · 20%

Aggregated analyst price targets for BWAY, weighted by recency and analyst accuracy.

TRY IT YOURSELF

Want to test your own assumptions? Use our free calculators to estimate BWAY's fair value with your own inputs.

LEARN MORE

Bulios

POWERED BY BULIOS

Get full analysis, financials, and AI insights for BWAY.

Explore on Bulios

FAQ

What is the fair price of BWAY?+

Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for BrainsWay Ltd. is $9.47. At the current market price of $16.40, BWAY trades 42.3% above its calculated fair value.

Is BWAY overvalued or undervalued?+

BrainsWay Ltd. is currently overvalued based on our valuation model. The stock trades at $16.40, which is 42.3% above the fair price of $9.47. The P/E ratio of 52.5x is a key metric in the valuation.

What is the margin of safety for BWAY?+

With a 20% margin of safety applied to the fair price of $9.47, the conservative entry level for BWAY is $7.58. At the current market price of $16.40, the stock trades 53.8% above this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.

How often is BWAY's fair price updated?+

We update fair price calculations for BWAY daily after market close. The current fair price of $9.47 incorporates the latest market data and sector multiples.

What factors affect BWAY's fair price calculation?+

BWAY's fair price of $9.47 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight). Key metrics include P/E of 52.5x, ROE of 9.5%.

Is BWAY a good buy right now?+

At $16.40, BWAY trades 42.3% above our fair value estimate of $9.47. The stock is currently overvalued. ROE stands at 9.5% (average). Fair Price Index provides valuation data — always do your own research before investing.

Does BWAY pay dividends?+

BWAY does not currently pay a dividend.

RELATED STOCKS

Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.